← Leaderboards
Beena G. Sood
Wayne State University
$1,800,179
Attributed
$1,800,179
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $399.9K · FY2005–17$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
FDA$1,399,818 · 1
NIH$400,361 · 1
By mechanism
R01$1,399,818 · 1
K23$400,361 · 1
Top collaborators
No co-investigators on record.
Most similar at Wayne State University
Same institution · by research overlap
- Donal S. O'Leary$16,207,949
- Jayanth Ramadoss$6,418,060
- Robert D. Welch$2,572,787
- Robert R Freedman$15,174,313
- Seetha Shankaran$12,158,445
Others in their field
Top investigators on “Prostaglandin E”
- L Jackson Roberts · Vanderbilt University$7,575,573
- Joshua A Boyce · Brigham And Women'S Hospital$7,064,421
- Marc L Peters-Golden · University Of Michigan At Ann Arbor$6,687,684
- Garret A Fitzgerald · University Of Pennsylvania$6,551,314
- Richard M Breyer · Vanderbilt University$5,951,624
- Beverly H Koller · Univ Of North Carolina Chapel Hill$5,334,425
Research focus
Prostaglandin EDrug Screening /EvaluationClinical Trial Phase IHuman SubjectInhalation Drug AdministrationNewborn Human (0-6 Weeks)OximetryPatient Oriented ResearchPediatric PharmacologyPostdoctoral InvestigatorPulmonary CirculationPulmonary HypertensionRespiratory OxygenationRespiratory TherapyVascular ResistanceVasodilatorsClinical TrialsDosage
Grant awards (8)
Phase 1/2 Study of Aerosolized Survanta for the Treatment of Neonatal Respiratory Distress Syndrome$203,733
R01 · FY2017 · FD · contact PI
Phase 1/2 Study of Aerosolized Survanta for the Treatment of Neonatal Respiratory Distress Syndrome$399,865
R01 · FY2016 · FD · contact PI
Phase 1/2 Study of Aerosolized Survanta for the Treatment of Neonatal Respiratory Distress Syndrome$399,792
R01 · FY2015 · FD · contact PI
Phase 1/2 Study of Aerosolized Survanta for the Treatment of Neonatal Respiratory Distress Syndrome$396,428
R01 · FY2014 · FD · contact PI
Aerosolized PGE1 in Neonatal Pulmonary Hypertension$25,726
K23 · FY2005 · HD
Aerosolized PGE1 in Neonatal Pulmonary Hypertension$126,331
K23 · FY2004 · HD
Aerosolized PGE1 in Neonatal Pulmonary Hypertension$123,434
K23 · FY2003 · HD
Aerosolized PGE1 in Neonatal Pulmonary Hypertension$124,870
K23 · FY2002 · HD